|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Higher levels of miR-21 were detected in patients with HRPC and ADPC with PSA level >4 ng/ml.
|
20842666 |
2011 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We finally report a significant association between ERG rearrangements in therapy-naive tumors, CRPCs, and CTCs and magnitude of prostate-specific antigen decline (P=0.007) in CRPC patients treated with abiraterone acetate.
|
19339269 |
2009 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Second-line hormonal therapy (eg, antiandrogens, CYP17 inhibitors) may be considered in patients with nonmetastatic CRPC at high risk for metastatic disease (rapid prostate-specific antigen doubling time or velocity) but otherwise is not suggested.
|
28441112 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A phase I study recently reported that seviteronel, a CYP17 lyase-selective inhibitor, ædemonstrated a sustained reduction in prostate-specific antigen in a patient with CRPC, and another study showed seviteronel's direct effects on AR function.
|
28463227 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Apalutamide showed improved metastasis-free survival and prolonged time to symptomatic progression in men with nonmetastatic castration-resistant prostate cancer with a short PSA doubling time.
|
30398479 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Those with an early prostate specific antigen doubling time of 3 to 8.9 months were at increased risk for castration resistant prostate cancer (HR 3.56, p = 0.015), all cause mortality (HR 1.67, p = 0.006) and prostate cancer specific mortality (HR 3.17, p = 0.044) but not metastases (p = 0.13).
|
28870860 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because very limited treatment options are available for recurrent hormone refractory prostate cancer (HRPC), it is imperative to assess whether the prostate-specific antigen (PSA) promoter-based TSTA gene therapy will be functional in HRPC.
|
15897571 |
2005 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone.
|
29630978 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Treatment for CRPC was given in 84 cases, with 90% receiving either abiraterone or enzalutamide in the first-line, with a PSA decline ≥50% occurring in 47%.
|
30370697 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both enzalutamide and apalutamide have been shown to significantly increase metastasis-free survival in phase III placebo-controlled randomised trials in nmCRPC patients with PSA doubling time (DT) ≤10 mo.
|
30119985 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cotargeting the AR (with MDV3100) and CLU (with OGX-011) synergistically enhanced apoptotic rates over that seen with MDV3100 or OGX-011 monotherapy and delayed CRPC LNCaP tumor and prostate-specific antigen (PSA) progression in vivo.
|
23786771 |
2013 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long-term treatment outcome.
|
28429372 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
|
28905815 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less.
|
29420164 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA half-time (representing rate to PSA nadir after ADT), the incidence of, and time to CRPC occurrence, and cause-specific mortality rates were determined during the 3-10 years follow-up.
|
25731771 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, 11βHSD2 activity, catalysing 11-ketotestosterone biosynthesis, was shown to be key in the production of prostate specific antigen and in the progression of prostate cancer to castration resistant prostate cancer.
|
30825506 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination has activity defined by PSA declines in CRPC but did not meet the protocol-specified end point for efficacy as defined by objective response rate.
|
29173976 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
On multivariable analysis, higher PSA at castrate-resistant prostate cancer (4.67 vs. 4.4ng/mL, OR=0.57, P=0.02), shorter time from castrate-resistant prostate cancer to scan (7.9 vs. 14.6 months, OR=0.97, P=0.006) and higher PSA at scan (OR=2.91, P<0.0001) were significantly predictive of bone scan positivity.
|
31851457 |
2020 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
|
19890632 |
2010 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I and II trial experience demonstrates the safety and tolerability of apalutamide, as well as its efficacy in effecting prostate-specific antigen response and radiographic-free survival in CRPC.
|
29695920 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Chemonaïve patients with CRPC on CAB and PSA-doubling time (DT) < 3 months were eligible.
|
19959380 |
2012 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present review, we ascertain the PSA dynamics and the mechanisms of the development of CRPC to assist in optimal utilization of the new treatments for mCRPC.
|
27270339 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intratumoral and subcutaneous injections of HVJ-E are feasible and PSA response was observed in a subgroup of CRPC patients.
|
28497777 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cause specific survival and time to prostate specific antigen (castrate resistant prostate cancer) progression were analyzed.
|
28552710 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cox proportional-hazards regression models were calculated to estimate effects of these variables on the time of progression to CRPC.On univariate and multivariate analyses, the presence of distant metastasis before ADT (hazard ratio [HR] 6.030, 95% confidence interval (CI) 3.229-11.263, P = .001), higher PSA nadir (HR 1.185, 95% CI 1.080-1.301, P = .001), a velocity of PSA decline >11 ng/mL per month (HR 2.124, 95% CI 1.195-3.750, P = .001), and a time to PSA nadir ≤9 months (HR 0.276, 95% CI 0.162-0.469, P = .004) were significantly associated with an increased risk of progression to CRPC.Patients with a rapidly decreasing PSA level in the initial phase of ADT are more likely to progress to CRPC.
|
28885333 |
2017 |